Biotech pigs capable of producing a cerebral thrombosis treatment drug have been successfully bred by South Korean scientists

South Korean scientists have successfully bred "biopigs" that produce a cerebral thrombosis (cerebral hemorrhage) treatment drug through their urine.

The South Korean Rural Development Administration recently stated: "By injecting the genetic gene for treating cerebral thrombosis (TPA) into pig fertilized eggs, we successfully bred 4 pigs that can excrete cerebral thrombosis treatment substances through their milk and urine." South Korea has become the world's second country after the United States to breed, through genetic modification, animals capable of producing cerebral thrombosis treatment substances. The United States, in 1997, through genetic modification technology, successfully bred a goat that produces cerebral thrombosis treatment substances through its milk.

Cerebral thrombosis treatment agents extracted from organisms are extremely expensive, with each gram costing as much as 53 million won, so these pigs will generate at least 200 million to 300 million won in revenue each year. The bioengineered animal production team of the South Korean Rural Development Administration also successfully bred, through genetic modification in 1998, pigs that produce anemia treatment agents.